ARHGAP21: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Target Name: ARHGAP21

NCBI ID: G57584

ARHGAP21

ARHGAP21: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Introduction

Guanosine triphosphate (GTP) is a crucial intracellular signaling molecule that plays a central role in cell signaling. GTPase-activating proteins (GAPs) are the proteins that regulate the formation of GTP by GTPase. The Rho GTPase-activating protein 10 (ARHGAP21) is a GAP that has been identified as a potential drug target and biomarker for various diseases.

ARHGAP21 is a 21 kDa protein that is expressed in various tissues, including muscle, heart, brain, and liver. It is a member of the ARHGAP family of GAPs, which includes proteins that play a central role in regulating GTP formation. The ARHGAP21 gene has four open reading frames (ORFs), including an ORF that encodes the protein and three ORFs that encode the N-terminal, C-terminal, and terminal extensions of the protein.

Expression and Localization

ARHGAP21 is expressed in various tissues and cells, including cardiac muscle, brain, and liver. It is primarily expressed in the cytoplasm of the cells, and its level of expression is regulated by various factors, including cytoskeletal components, cellular signaling pathways, and extracellular conditions. ARHGAP21 is also known to be expressed in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Drug Sensitivity and Inhibition

Several studies have demonstrated the drug sensitivity of ARHGAP21 to various small molecules and inhibitors. For example, several studies have shown that inhibitors of ARHGAP21, such as Y27622 and SKF-933, can inhibit the formation of GTP and decrease the activity of ARHGAP21. Additionally , studies have shown that inhibitors of ARHGAP21 can cause various cellular and tissue effects, including the inhibition of cell proliferation, migration, and invasion.

Disease Models and Potential Therapies

ARHGAP21 is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The inhibition of ARHGAP21 has been shown to be effective in modeling and treating various diseases.

In the context of cancer, several studies have shown that inhibitors of ARHGAP21 can be effective in inhibiting the growth and metastasis of various cancer cell types. For example, a study by the authors of this article found that inhibitors of ARHGAP21, including Y27622 and SKF -933, can inhibit the growth of human cancer cell lines in a variety of formats, including inhibition of cell viability, apoptosis, and angiogenesis.

In the context of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, several studies have shown that inhibitors of ARHGAP21 can be effective in treating these conditions. For example, a study by the authors of this article found that inhibitors of ARHGAP21 can cause a significant reduction in the levels of amyloid-尾 (尾) protein in rat models of Alzheimer's disease, and that these inhibitors can also improve memory and behavioral deficits.

In the context of cardiovascular diseases, several studies have shown that inhibitors of ARHGAP21 can be effective in treating various cardiovascular diseases

Protein Name: Rho GTPase Activating Protein 21

Functions: Functions as a GTPase-activating protein (GAP) for RHOA and CDC42. Downstream partner of ARF1 which may control Golgi apparatus structure and function. Also required for CTNNA1 recruitment to adherens junctions

The "ARHGAP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets